viewBraveheart Investment Group

Braveheart Investment flags progress at Paraytec and Pharm 2 Farm

Paraytech, which makes specialist detectors for the analytical and life sciences instrumentation market, is off to meet GlaxoSmithKline to talk about measuring protein aggregation in biopharmaceuticals

Braveheart Investment Group -

Braveheart Investment Group PLC’s (LON:BRH) has updated on its six strategic investments, revealing progress of varying pace on all fronts.

Among the highlights, detectors maker Paraytec, where Braveheart bought the remaining shares it did not already own in October, has begun the second round of end-user trials for its main R&D project, with the scientific team due to visit GlaxoSmithKline and Medimmune over the coming weeks, having already conducting trials with Fujifilm Diosynth.

The trial, which is being funded by a Innovate UK grant, is focused on the measuring of protein aggregation in biopharmaceuticals, an impurity that it is crucial for drug companies to control.

READ: Braveheart Investment keeps valuations unchanged

Meanwhile, Pharm 2 Farm (P2F), where Braveheart upped its stake from 33.33% to 51.72% in December to help the business open a new manufacturing facility and expand its sales team, has received “significant interest” from the turf management industry after a recent trade show.

At P2F, which has developed nanoparticle technology to improve plant feeds, Braveheart highlighted product sales to customers in the Australian hydroponics market.

Elsewhere, Kirkstall, which is 65%-owned by Braveheart, has recently appointed new distributors in South Korea and China to sell its Quasi Vivo system for cell and tissue culture in laboratories, and is preparing for its annual Advances in Cell and Tissue Culture conference in June.

Gyrometric Systems, where Braveheart owns 20% and most of the rest is owned by AIM-listed Remote Monitored Systems, there are plans to shortly begin selling its new timing laser product that can be used to monitor the speed of rotating shafts, adding to a suite of products that was broadened by the “significant breakthrough” last year of its Absolute Dynamic Shaft Alignment system.

As Remote Monitored Systems said in December, revenues at GyroMetric remain modest but “considerable progress” has been made in expanding the customer base.

Braveheart said Phasefocus, of which it owns 21%, has added distribution agreements in Italy, Canada, Japan, France and Israel in recent months, which are expected to drive sales growth in its Livecyte live cell analysis product line. 

Over at 38%-owned Sentinel Medical, work continues with the University of Sheffield to optimise the test protocols before re-starting the testing of bladder cancer patient samples after a decision was taken to revise them after the initial trials.

Quick facts: Braveheart Investment Group

Price: 10.25 GBX

Market: AIM
Market Cap: £2.88 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Braveheart Investment Group named herein, including the promotion by the Company of Braveheart Investment Group in any Content on the Site, the...



Braveheart's Trevor Brown details investment in 'exciting' Pharm2Farm Limited

Proactive London's Andrew Scott speaks to Braveheart Investment Group PLC's (LON:BRH) and Pharm2Farm Limited's (P2F) Gareth Cave following Braveheart's investment in the business. P2F has developed a patented process to increase the bioavailability of trace minerals in plant feeds for...

on 15/7/19

2 min read